3 completed, 1 terminated. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow CF101: new trials by email Literature Review of CF101 trials Research Report on CF101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis CF101 2mg, CF101 3mg, Apremilast 30mg - Plaque Psoriasis | Phase 3 | Completed | Can-Fite BioPharma | 528 | 2018-09-15 | 2022-06-28 |
| CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis CF101 1 mg, CF101 2 mg, Placebo - Rheumatoid Arthritis | Phase 3 | Terminated | Can-Fite BioPharma | 244 | 2017-10-30 | 2020-12-19 |
| Trial of CF101 to Treat Patients With Dry Eye Disease CF101 - Keratoconjunctivitis Sicca | Phase 3 | Completed | Can-Fite BioPharma | 236 | 2011-07-01 | 2022-06-30 |
| Trial of CF101 to Treat Patients With Psoriasis CF101, Placebo - Plaque Psoriasis | Phase 2 / Phase 3 | Completed | Can-Fite BioPharma | 293 | 2011-07-01 | 2020-11-18 |
Arthritis, Rheumatoid (1) · Dry Eye Syndromes (1) · Keratoconjunctivitis Sicca (1) · Psoriasis (1)
Israel (4) · Romania (3) · Bosnia and Herzegovina (2) · Bulgaria (2) · Canada (2) · Moldova (2) · Poland (2) · Serbia (2) · Croatia (1) · United States (1)
Michael H Silverman, MD (3) · Michael David, MD (1)